In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality.

Repare Therapeutics Inc. announced Tuesday it will receive a $65 million upfront payment, including a $15 million equity investment, from Bristol Myers Squibb Co. (NYSE:BMY). The Versant Ventures-built biotech, which is based in Montreal and led by President and CEO Lloyd Segal, will be eligible for about $3 billion in license fees and discovery, development, regulatory and sales-based milestones, plus royalties...